Research Nester published a report titled “Non-Cancerous Blood Disease Market: Global Demand Analysis & Opportunity Outlook 2031” which delivers detailed overview of the global non-cancerous blood disease market in terms of market segmentation by disorder type, treatment type, gender, end-user, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The global non-cancerous blood disease market is anticipated to grow with a CAGR of 6.40% over the forecast period, i.e., 2022 – 2031. The market is segmented by disorder type into anemia, bleeding disorders, platelet disorders, white blood cell disorders, plasma cell disorders, rare hematological disorders, and spleen disorders, out of which, the bleeding disorders segment is projected to display the largest revenue of USD 29949.69 Million by the end of 2031. Moreover, in the year 2021, the segment generated a revenue of USD 16570.67 Million.
The global non-cancerous blood disease market is estimated to garner a revenue of USD 105972.8 Million by the end of 2031, up from a revenue of USD 57224.1 Million in the year 2021. Increasing burden for hemoglobinopathies globally, along with the rising need for the early diagnosis of different types of non-cancerous blood diseases, are some of the major factors anticipated to drive the growth of the market in the coming years.
Geographically, the global non-cancerous blood disease market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Out of these, the market in Europe region is anticipated to garner the largest revenue of USD 39845.4 Million by the end of 2031. Additionally, in the year 2021, the market in the region generated a revenue of USD 21344.6 Million.
The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.
Increasing Prevalence of Non-Cancerous Blood Disorders to Drive Market Growth
In the year 2019, according to the statistics by the World Health Organization (WHO), the global prevalence of anemia recorded to be 29.9% in women of reproductive age, 29.6% in non-pregnant women of reproductive age, and 36.5% in pregnant women. Additionally, in children between the ages 6 and 59 months, the prevalence of the disease in the same year was 39.8%.
The surge in the prevalence of several types of non-cancerous blood disorders around the globe is raising the need for advanced drugs and therapies for the efficient treatment of these diseases, which is expected to drive the growth of the market in the coming years. Additionally, the growing research and developments in this field, backed by the increasing expenditure on R&D activities, along with the surge in awareness for these types of diseases are also projected to boost the market growth in the coming years.
However, the high cost of treatment of these diseases, along with the complexities in monitoring several non-malignant blood disorders are expected to operate as key restraint to the growth of global non-cancerous blood disease market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global non-cancerous blood disease market which includes company profiling of SANOFI, Novo Nordisk A/S, Novartis AG, Pfizer Inc., Amgen Inc., Alexion Pharmaceuticals, Inc., Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, CSL Behring, and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global non-cancerous blood disease market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.